2 Sleep Apnea Stocks in Focus Today

Core Insights - Eli Lilly and Co's weight-loss drug Zepbound has been approved by the U.S. FDA for treating obstructive sleep apnea in adults with obesity, marking it as the first treatment of its kind in the country [1] - Following the approval, Eli Lilly's stock rose by 1.7% to $480.55, while shares of competitor ResMed Inc fell by 5$225.44 [1] Eli Lilly (LLY) - LLY experienced a rebound, marking its second gain in 10 trading days after bouncing off the 320-day moving average [2] - The stock has been volatile since a bear gap in late October but is up 33.2% year-to-date [2] ResMed Inc (RMD) - RMD is trading at its lowest levels since late August, distancing itself from its two-year high of $260.49 reached on October 25 [3] - Year-to-date, RMD's stock is up 30.9% despite the recent decline [3]